Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab in Waldenstrom's Macroglobulinemia
NCT00004889Phase 2Completed
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Dec 1999
- Primary completion
- Jan 2002
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of rituximab in Waldenström macroglobulinemia (WM), sponsored by UCLA Jonsson Comprehensive Cancer Center. Started Dec 1999; status: completed.
02
Drugs
rituximab
03
Conditions
Waldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT00004889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00004889.